FutureChem Receives Approval for Phase 3 Clinical Trial of Prostate Cancer Diagnostic Drug in Europe
[Asia Economy Reporter Minji Lee] FutureChem announced on the 28th that it has received approval from the Austrian Agency for Health and Food Safety in Europe for the Phase 3 clinical trial of Florastamin, a radiopharmaceutical under development for prostate cancer diagnosis.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- The Unexpected Story of an American Man Who Won the Lottery 18 Times in 29 Years: "My Real Luck Is My Wife"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
The company stated, "If appropriate results are obtained based on the established efficacy evaluation criteria, an NDA application to the EMA is planned."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
